Mumbai-based Encube Ethicals is preparing a $400 million IPO with help from top global banks. The company, which develops skin creams and gels, plans to use the money to expand its global manufacturing footprint and research footprint.
Key Highlights
- Indian drug manufacturer Encube Ethicals is pursuing an initial public offering (IPO) to generate around $400 million
- The company has also enlisted investment heavyweights like Goldman Sachs, Morgan Stanley and Kotak Mahindra to oversee the sale.
- These respective proceeds from the Initial Public Offering (IPO) are likely to encourage a company to use those revenues towards expanding factories.
Ethicals of Encube plans to raise $400 million in an IPO
Encube Ethicals continues to target a public listing in what could be a $400 million deal. The Mumbai-based drugmaker has begun the process of enlisting prestigious banks to assist with a plan to sell shares in an initial public offering on the Indian stock market, according to the news. With this move, Encube hopes to capitalise on the amount of interest investors are paying for healthcare and medicine companies right now.
This IPO is big news for the Indian pharmaceutical industry. Over the years, Encube has earned a solid reputation as a partner of choice for global health brands. It will give them the cash to compete on a global scale. It also gives their early investors a chance to finally recoup some of the cash they invested in the company years earlier.
Specialist in Topical Medicines
The specific focus on skin treatments is what sets Encube Ethicals apart from the rest of the drug companies. Instead of producing pills or liquids, they specialise in topicals, which are medicines that you apply on your skin. They also have enormous factories that produce millions of tubes of cream and gel a year for customers across the globe, including in the United States and Europe.
Because they specialise in such a specific niche, they have mastered the chemistry that makes these products stable and effective. This specialised knowledge is a major selling point to investors. As demand for advanced skincare and medical treatments for skin conditions continues to rise globally, it is anticipate that Encube’s business will continue to expand even further.
Partnering with Global Banks
Encube is collaborating with some of the most elite banks on the planet to ensure that the $400 million IPO is a smash hit. They have tapped Goldman Sachs and Morgan Stanley to lead the process, reports say. These banks also have experience to scout large global investors looking for a share of the Indian healthcare story.
They are also partnering with local experts such as Kotak Mahindra Capital. This blend of global and local banking muscle helps ensure shares are priced properly and go to the right investors. The participation of these international banks signals that the corporate world has a lot of trust in Encube’s fiscal health and its ambitions going forward.
Future Expansion and Growth
Funds raised from the stock market will mostly be used to construct new labs and for the upgradation of their existing manufacturing plants. While they already have a significant facility in Goa, Encube is upgrading and expanding its capacity to meet growing demand. They also want to invest more in research so that they can develop their own unique formulas for new skin medications.
In the long term, this IPO could value the entire business at north of $1 billion. Further details on exactly how many shares will sell for and when the sale will happen will be revealed as the deal continues.
FAQs
- How much money is Encube Ethicals looking to raise?
The firm is pursuing a $400 million IPO.
- The company is based in which location?
Originating in Mumbai, India, with principal manufacturing locations in Goa, Encube Ethicals
- Why are they making this public now?
They hope to raise capital for expansion and benefit from strong demand in the Indian stock market.
Follow Inspirepreneur Magazine for the business news.
